Full Text View
Tabular View
No Study Results Posted
Related Studies
Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
This study is ongoing, but not recruiting participants.
Study NCT01141491   Information provided by MabVax Therapeutics, Inc.

First Received on June 9, 2010.   Last Updated on February 1, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Sarcoma
More general conditions related to this trial
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Connective and Soft Tissue
Interventions listed in this trial
Trivalent ganglioside vaccine
OPT-821
Additional drug interventions recognized in this trial
Adjuvants, Immunologic
More general drug interventions related to this trial
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
MabVax Therapeutics, Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services